Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -50.30% is 25% above its 5-year average of -67.08%, near the high end of its 5-year range (-172.23%–-10.49%).
61.82% above its 12-month average of -131.74%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.17%.
RETURN ON ASSETS (ROA)
-50.30%
RETURN ON ASSETS (ROA) AVG TTM
-131.74%
RETURN ON ASSETS (ROA) AVG 3Y
-92.52%
RETURN ON ASSETS (ROA) AVG 5Y
-67.08%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+61.82%
CURRENT VS 3Y AVG
+45.63%
CURRENT VS 5Y AVG
+25.02%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-24.95%
median of 438 covered companies
CURRENT VS SECTOR MEDIAN
-101.60%
vs the sector median at left
ALX Oncology Holdings Inc.
Market Cap
$162.82M
Return on Assets (ROA)
-50.30%
TTM Avg
-131.74%
3Y Avg
-92.52%
5Y Avg
-67.08%
Market Cap
$153.84M
Return on Assets (ROA)
-90.55%
TTM Avg
-70.80%
3Y Avg
-45.07%
5Y Avg
-40.08%
Market Cap
$172.99M
Return on Assets (ROA)
-38.62%
TTM Avg
-32.73%
3Y Avg
-28.05%
5Y Avg
-37.08%
Market Cap
$173.04M
Return on Assets (ROA)
-68.50%
TTM Avg
-29.78%
3Y Avg
-39.51%
5Y Avg
-30.76%
Market Cap
$152.45M
Return on Assets (ROA)
-20.01%
TTM Avg
-38.20%
3Y Avg
-34.64%
5Y Avg
-39.69%
Market Cap
$152.16M
Return on Assets (ROA)
-127.14%
TTM Avg
-129.15%
3Y Avg
-91.50%
5Y Avg
-82.73%
Market Cap
$174.17M
Return on Assets (ROA)
-41.88%
TTM Avg
-12.18%
3Y Avg
-27.40%
5Y Avg
-32.78%
Market Cap
$149.51M
Return on Assets (ROA)
-25.59%
TTM Avg
-36.78%
3Y Avg
-35.70%
5Y Avg
-27.05%
Market Cap
$176.96M
Return on Assets (ROA)
-534.43%
TTM Avg
-94.69%
3Y Avg
-82.47%
5Y Avg
-71.30%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ALX Oncology Holdings Inc. (ALXO) | $162.82M | -50.30% | -131.74% | -92.52% | -67.08% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $153.84M | -90.55% | -70.80% | -45.07% | -40.08% |
| Compass Therapeutics, Inc. (CMPX)vs › | $172.99M | -38.62% | -32.73% | -28.05% | -37.08% |
| Coherus Oncology, Inc. (CHRS)vs › | $173.04M | -68.50% | -29.78% | -39.51% | -30.76% |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.45M | -20.01% | -38.20% | -34.64% | -39.69% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.16M | -127.14% | -129.15% | -91.50% | -82.73% |
| Precision BioSciences, Inc. (DTIL)vs › | $174.17M | -41.88% | -12.18% | -27.40% | -32.78% |
| Codexis, Inc. (CDXS)vs › | $149.51M | -25.59% | -36.78% | -35.70% | -27.05% |
| Cue Biopharma, Inc. (CUE)vs › | $176.96M | -534.43% | -94.69% | -82.47% | -71.30% |
| Immuneering Corporation (IMRX)vs › | $146.66M | -28.35% | -69.97% | -58.34% | -49.63% |
ROA
-50.3%
ROE
-59.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -172.23% |
| 2024-12-31 | -91.25% |
| 2023-12-31 | -66.30% |
| 2022-12-31 | -40.29% |
| 2021-12-31 | -21.95% |
| 2020-12-31 | -10.49% |
| 2019-12-31 | -180.25% |
| 2018-12-31 | -122.99% |
